About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

Discovery of PRT811, a Potent, Selective, and Orally Bioavailable Brain Penetrant PRMT5 Inhibitor for the Treatment of Brain Tumors.

Zhang Y, Lin H, Wang M, Angelis D, Hawkins M, Rominger D, Emm T, Thodima V, Luengo J, Ruggeri B, Scherle P, and Vaddi K. AACR Virtual Annual Meeting II; June 22-24, 2020.